LuciTepo 225 mg Tablets contain tepotinib which is a
targeted therapy used in the treatment of non small cell lung cancer with MET
gene alterations. It helps slow tumor growth and supports better disease
management in patients who are not suitable for conventional treatments. This
medicine is prescribed by oncology specialists and is widely used in the United
Kingdom, United States, Australia, Singapore and Philippines. It offers a
precision based approach that focuses on specific cancer pathways and helps
improve treatment outcomes with manageable safety profiles.
Active Ingredient
Tepotinib is a MET inhibitor that blocks abnormal signaling
caused by MET gene mutations. It belongs to targeted cancer therapy drugs that
act on specific molecular pathways involved in tumor growth.
Uses of LuciTepo 225 mg Tablets
• Treatment of non small cell lung cancer
• Management of MET altered cancers
• Support for targeted oncology therapy
• Control of tumor progression
How LuciTepo 225 mg Tablets Works
Tepotinib works by inhibiting the MET receptor tyrosine
kinase which is responsible for cancer cell growth and survival in certain
tumors. By blocking this pathway the medicine reduces abnormal cell
proliferation and helps control tumor spread. This targeted action allows
better disease management.
How to Use LuciTepo 225 mg Tablets
- Take
the tablet with food as directed by your doctor.
- Swallow
whole with water without crushing.
- Follow
the prescribed dosage schedule strictly.
Possible Side Effects
• Swelling in limbs
• Nausea
• Fatigue
• Diarrhea
Precautions
• Monitor liver function regularly
• Inform your doctor about any lung issues
• Avoid use during pregnancy
Safety Information
Use only under medical supervision. Regular monitoring is
essential to track response and detect side effects early for safe treatment.
Storage
• Store at room temperature below 25°C
• Protect from moisture
• Keep out of reach of children